Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs